AKRO | Akero Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	26.73 - 27.69
52 Week Range	11.25 - 53.00
Beta	-0.79
Implied Volatility	50.69%
IV Rank	7.05%
Day's Volume	365,557
Average Volume	661,703
Shares Outstanding	69,430,800
Market Cap	1,858,662,516
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-06-20

Valuation
Profitability
Growth
Health
P/E Ratio	-7.78
Forward P/E Ratio	N/A
EPS	-3.44
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	61
Country	USA
Website	AKRO

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

AKRO's peers: ACAD, ADCT, TERN, MDGL, INZY, VKTX, ICPT, RETA, RVMD, RNA, PTGX, STOK, TCRR, BDTX, BCEL, PASG, ALT, APLS, ARCT, ARGX, ASND, AUPH, AXSM, BGNE, CPRX, DNLI, ETNB, FDMT, FGEN, GALT, GMAB, GOSS, IMAB, IMVT, INSM, IONS, KOD, LEGN, LGND, MORF, MRNS, MRVI, OMER, PCVX, ROIV, RPRX, RVNC, RYTM, SAGE, SRPT, TECH, TGTX, TNYA, TSHA, TVTX, UTHR, VBIV, VIR, VRNA, ZLAB, ZYME, MLTX

*Chart delayed

Analyzing fundamentals for AKRO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see AKRO Fundamentals page.

Watching at AKRO technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on AKRO Technicals page.